Visikol’s Commitment to Reducing Animals in Research
Carol Tomaszewski2022-05-26T07:45:17-05:00Like many of the BICO companies, Visikol is highly focused on reducing the usage of animals in research and [...]
Like many of the BICO companies, Visikol is highly focused on reducing the usage of animals in research and [...]
Labroots Drug Discovery & Development 2022 Labroots and the Drug Discovery planning committee are pleased [...]
Figure 1: Differential proliferative response in 2D vs. 3D cell culture The drug discovery and development process is [...]
Visikol's Director of Drug Discovery, Peter Worthington Ph.D., to Present at SELECTBIO's 3D-Cell Culture, Organoids, and Organs-on-Chips Conference [...]
The five-year relative survival for all cancer sites has been steadily improving since the 1980s. Because cancer is becoming [...]
One of the most common assays used with in vitro models is an assessment of total ATP which is [...]
As drug discovery and development efforts continue to seek balance between throughput and translatability of in vitro studies to [...]
[contact-form-7 id=”6190″ title=”Request Quote Form”]